Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 13, 2026

Stock market today: Dow, S&P 500, Nasdaq slide as inflation eases, JPMorgan sinks with more bank earnings ahead

View original at finance.yahoo.com
Stock market today: Dow, S&P 500, Nasdaq slide as inflation eases, JPMorgan sinks with more bank earnings ahead US stocks fell on Tuesday as a milder inflation reading supported bets on medium-term Fed easing, while JPMorgan (JPM) results kicked off the fourth quarter earnings season with underwhelming results…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • DOJ probe is political pressure from President Trump

    80% confidence

  • Growth in premium business and lack of certain headwinds would propel business forward in 2026

    80% confidence

  • Everyone believes in Fed independence, and anything that chips away at that is probably not a great idea. It will have reverse consequences, raise inflation expectations and probably increase rates over time

    80% confidence

  • Gas prices remain seasonally lower, but with oil prices inching higher, the national average could soon see some limited upward movement

    80% confidence

  • Jerome Powell is either incompetent or crooked

    80% confidence

  • Microsoft will work to make sure towns and cities near data center development sites are not adversely affected by electricity costs

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
Stock market today: Dow, S&P 500, Nasdaq slide as inflation eases, JPMorgan sinks with more bank earnings ahead — Source | Via News | Finance Via News